|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/48 | (2006.01) |
| A61K 38/4846 | (2013.01) | ||
| C12N 9/64 | (2006.01) | ||
| C12Y 304/21022 | (2013.01) | ||
| C12N 9/644 | (2013.01) | ||
| A61K 9/0019 | (2013.01) | ||
| A61K 47/643 | (2017.08) |
| (11) | Patento numeris | 3645034 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 18736860.0 |
| Europos patento paraiškos padavimo data | 2018-06-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-05-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-08-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2018/067523 |
| Data | 2018-06-29 |
| (87) | Numeris | WO 2019/002532 |
| Data | 2019-01-03 |
| (30) | Numeris | Data | Šalis |
| 201762526377 P | 2017-06-29 | US |
| (72) |
LI, Yanyan , US
BENSEN-KENNEDY, Debra , US
JACOBS, Iris , US
VOIGT, Christine , US
|
| (73) |
CSL Behring Lengnau AG ,
Biotech Innovation Park, 2543 Lengnau BE,
CH
|
| (54) | 21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF |
| 21-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF |